Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy
Authors' conclusion
Our data highlight the potential of serum EV miRs as diagnostic and therapeutic biomarkers, highlighting a novel potential mechanism by which MTX may exert its therapeutic effect in early RA that warrants further investigation.
Study context
- Population
- Patients with untreated early RA, untreated polymyalgia rheumatica (PMR) and non-inflammatory controls; 798 microRNAs (miRs) isolated from serum-derived extracellular vesicles (EVs)
- Participants
- 46 / 23 / 12
- Comparison
- Untreated early RA vs untreated PMR vs non-inflammatory controls; Methotrexate (MTX) responders vs non-responders
- RAn = 46
- PMRn = 23
- NICsn = 12reference
- Outcome
- EV miRs differentially expressed vs NICs
- Follow-up
- Baseline
Methodological detailsNanoString profiling, multiple testing taken into account, cross-validated partial least squares-discriminant analysis
- NanoString profiling
- Multiple testing taken into account
- Cross-validated partial least squares-discriminant analysis
Main finding
As reported in the abstract
EV miRs robustly differentially expressed between early RA (but not PMR) and NICs after correction for age and sex
28
miRs whose change in expression over MTX treatment differed significantly between responders and non-responders
13
Of those, miRs with increased relative abundance in responders and known roles in regulating synovial fibroblasts' pathogenic potential (miR-212-3p, miR-338-5p, miR-410-3p, miR-537)
4
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →